お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
987864

弱毒生水痘ワクチンの世界市場:2020~2027年

Global Varicella Attenuated Live Vaccine Market - 2020-2027

出版日: 受注後作成 | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
弱毒生水痘ワクチンの世界市場:2020~2027年
出版日: 受注後作成
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 目次
概要

カンジダ症の有病率の上昇、研究開発費の増加、および新興市場における未開拓の機会は、市場の成長をけん引する要因となっています。ただし、発展途上経済諸国における外陰膣カンジダ症に関する認識の欠如は、予測期間中の市場成長を妨げると見込まれています。

当レポートでは、世界の弱毒生水痘ワクチン市場について調査分析し、市場の概要、市場成長への影響要因、各セグメント・地域別による市場規模と前年比成長、および主要企業などについて分析しています。

目次

第1章 世界の弱毒生水痘ワクチン市場:調査範囲・手法

  • 調査手法
  • 調査目的・範囲

第2章 世界の弱毒生水痘ワクチン市場:市場の定義・概要

第3章 世界の弱毒生水痘ワクチン市場:エグゼクティブサマリー

  • 市場内訳:製品別
  • 市場内訳:アプリケーション別
  • 市場内訳:プロバイダー別
  • 市場内訳:地域別

第4章 世界の弱毒生水痘ワクチン市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の弱毒生水痘ワクチン市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界の弱毒生水痘ワクチン市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以降または将来のシナリオ
  • Covid-19期間中の価格ダイナミクス
  • 需要と供給のスペクトル
  • パンデミック期間中の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ

第7章 世界の弱毒生水痘ワクチン市場:製品別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):製品別
  • 市場魅力指数:製品別
    • 一価ワクチン
    • 混合ワクチン

第8章 世界の弱毒生水痘ワクチン市場:アプリケーション別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):アプリケーション別
  • 市場魅力指数:アプリケーション別
    • 水痘予防の接種
    • 帯状疱疹の予防接種
    • MMRVの予防接種

第9章 世界の弱毒生水痘ワクチン市場:プロバイダー別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):プロバイダー別
  • 市場魅力指数:プロバイダー別
    • 公共プロバイダー
    • 民間プロバイダー

第10章 世界の弱毒生水痘ワクチン市場:地域別

  • イントロダクション
    • 市場規模分析および前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析および前年比成長分析(%):製品別
    • 市場規模分析および前年比成長分析(%):アプリケーション別
    • 市場規模分析および前年比成長分析(%):プロバイダー別
    • 市場規模分析および前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の弱毒生水痘ワクチン市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Bio-Med Pvt. Limited
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主なハイライト
    • 財務概要
  • Emcure Pharmaceuticals Limited
  • GC Pharma (Green Cross Holdings)
  • GlaxoSmithKline PLC
  • Novo Medi Sciences Pvt. Ltd.
  • Merck & Co. Inc.
  • Sanofi SA
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda Pharmaceutical Company Limited

第13章 世界の弱毒生水痘ワクチン市場:重要考察

第14章 世界の弱毒生水痘ワクチン市場:DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Market Overview

Varicella zoster, also known as Human alphaherpesvirus 3, causes herpes zoster and chicken pox in humans. The infection instigated by this virus can be avoided by the use of vaccinations that are particularly formulated to provide immunity against the virus. These vaccines vary from each other on the basis of their contents. For instance, monovalent varicella vaccine comprises only one strain of virus whereas the combination varicella vaccine includes more than one strain of virus and offers immunity against more than one virus.

The global varicella attenuated live vaccine market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.

Expected increase in the prevalence of chicken pox

According to CDC (Centers for Disease Control and Prevention), more than 3.5 million cases of chickenpox, along with 9,000 hospitalizations, and 100 mortalities are averted by chickenpox vaccination in the U.S. This, in turn, contributes to the growth of the varicella attenuated live vaccine market. There are several companies that are strengthening their position by driving national programs for support and coordination among national, local, regional, and international stakeholders, has accomplished in improving immunization coverage rates.

Increasing government focus on varicella attenuated live vaccine

The government support is increasing with the rising focus on driving immunization programs to lessen the disease burden impact that aids in the growth of the varicella attenuated live vaccine market. A few of manufacturers in collaboration with Gavi, WHO, the World Bank, and UNICEF are committed to boost immunization programs and speed up the introduction of new vaccines. This would contribute to the growth of the varicella attenuated live vaccine market.

COVID-19 Impact Analysis

A decrease in the market value of varicella attenuated live vaccine is expected in 2020, backed by the decline in the hospital visits, which in turn, also hampered the functioning of immunization programs. Therefore, the demand for varicella attenuated live vaccine decreased amid the COVID-19 pandemic, which in turn, declined the sales of the vaccine in 2020.

Segment Analysis

Based on the application, the varicella attenuated live vaccine market has been classified into Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization, and econazole.

Chickenpox Immunization segment contributed significant share to the global varicella attenuated live vaccine market in 2019

Chicken pox immunization contributed the largest varicella attenuated live vaccine market share in 2019, owing to immunization employed with an initial aim of developing immunity against chicken pox. It is highly contagious and is typically spread by direct contact or via air by sneezing and coughing. The illness commonly causes an itchy rash and leads to the formation of more than 400 blisters all over the body. Additionally, it causes fussiness, headache, and coughing in the patients.

Based on the product, the varicella attenuated live vaccine market has been classified into monovalent varicella vaccine and combination varicella vaccine.

Monovalent Varicella Vaccine lead the market throughout the forecast period

Monovalent Varicella Vaccine segment led the overall market with a share in 2019. It is also expected to foresee rapid growth during the forecast period, as such vaccines demonstrate lesser chances of causing febrile seizures in children as compared to combination vaccines. In addition, easy availability and presence of wide product portfolio are the other factors that enhance the varicella attenuated vaccine market growth.

Geographical Analysis

Based on geography, the study analyzes the varicella attenuated live vaccine market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominated the global varicella attenuated live vaccine market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American varicella attenuated live vaccine market in 2019. The presence of skilled healthcare professionals and the presence of key market players, such as Merck & Co., Inc., are other factors that are supporting the market growth.

Moreover, Asia Pacific is expected to project the fastest growth rate in the varicella attenuated live vaccine market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific varicella attenuated live vaccine market during the forecast period. The gradual rise in vaccination for varicella and the rapidly evolving life science industry are certain factors augmenting the market growth in the region.

Competitive Landscape

The varicella attenuated live vaccine market is highly competitive, owing to the large presence of varicella attenuated live vaccine brands. The key varicella attenuated live vaccine players include Bio-Med Pvt. Limited, GlaxoSmithKline PLC, GC Pharma (Green Cross Holdings), Novo Medi Sciences Pvt. Ltd., Emcure Pharmaceuticals Limited, Sanofi SA, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Company Limited. The crucial players are adopting new product launches and expansion strategies for global growth in the varicella attenuated live vaccine market.

Merck & Co. Inc.

Overview: Merck & Co. Inc. is a research-based pharmaceutical company that offer healthcare solutions via its prescription medicines, biologic therapies, vaccines, animal health products. The company sell its products to hospitals, drug wholesalers and retailers, government agencies, and other institutions. It generates over 40.0% of its revenue from the US.

Product Portfolio: The company's portfolio comprises VARIVAX and ZOSTAVAX.

Why Purchase the Report?

  • Visualize the varicella attenuated live vaccine market segmentation composition by product, application, provider, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the varicella attenuated live vaccine market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of varicella attenuated live vaccine market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global varicella attenuated live vaccine market report would provide access to an approx. 51 market data tables, 50 figures, and 260 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Varicella Attenuated Live Vaccine Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Varicella Attenuated Live Vaccine Market - Market Definition and Overview

3. Global Varicella Attenuated Live Vaccine Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Provider
  • 3.4. Market Snippet by Region

4. Global Varicella Attenuated Live Vaccine Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of chicken pox
      • 4.1.1.2. Government initiatives to increase immunization programs
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of the Vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Varicella Attenuated Live Vaccine Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Varicella Attenuated Live Vaccine Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Varicella Attenuated Live Vaccine Market - By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Monovalent Varicella Vaccine*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Combination Varicella Vaccine

8. Global Varicella Attenuated Live Vaccine Market - By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Chickenpox Immunization*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Herpes Zoster Immunization
    • 8.3.3. MMRV Immunization

9. Global Varicella Attenuated Live Vaccine Market - By Provider

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider Segment
  • 9.3. Market Attractiveness Index, By Provider Segment
    • 9.3.1. Public Provider*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Private Provider

10. Global Varicella Attenuated Live Vaccine Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Varicella Attenuated Live Vaccine Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Varicella Attenuated Live Vaccine Market- Company Profiles

  • 12.1. Bio-Med Pvt. Limited*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Emcure Pharmaceuticals Limited
  • 12.3. GC Pharma (Green Cross Holdings)
  • 12.4. GlaxoSmithKline PLC
  • 12.5. Novo Medi Sciences Pvt. Ltd.
  • 12.6. Merck & Co. Inc.
  • 12.7. Sanofi SA
  • 12.8. Mitsubishi Tanabe Pharma Corporation
  • 12.9. Takeda Pharmaceutical Company Limited

LIST NOT EXHAUSTIVE

13. Global Varicella Attenuated Live Vaccine Market - Premium Insights

14. Global Varicella Attenuated Live Vaccine Market - DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.